Last reviewed · How we verify
JNJ-78278343
At a glance
| Generic name | JNJ-78278343 |
|---|---|
| Also known as | Pasritamig, KLK2-CD3 |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (PHASE1)
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE3)
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer (PHASE1)
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (PHASE1)
- A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (PHASE1)
- A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (PHASE1)
- A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (PHASE1)
- A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-78278343 CI brief — competitive landscape report
- JNJ-78278343 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI